HER2 STANDS WITH YOU

Sign up for support tailored to people with HER2+ mBC and their loved ones

About HER2 Stands With You

HER2 Stands With You is a support program specifically designed for people diagnosed with HER2+ metastatic breast cancer (mBC) who are taking, or considering, ENHERTU and the people who are close to them.

This program shares information and resources on HER2+ mBC and ENHERTU, helping you feel more comfortable with what to expect on the road ahead. This includes:

Financial support programs to help you afford treatment
Information about what to expect when starting ENHERTU
Breast cancer community newsletters

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
- for metastatic disease, or
- have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

^*Required field

Step 1 of 3 Which best describes you?*

I have been diagnosed with HER2+
metastatic breast cancer.

I am a care partner for someone who
has been diagnosed with HER2+
metastatic breast cancer.

The privacy and security of your personal information is important to Daiichi Sankyo, Inc. The information that you provide to us will be shared with and among our business partners for purposes related to Daiichi Sankyo, Inc. products, programs, services, and market research. Your personal information will not be used by any of our business partners for their own marketing purposes. By providing your information above, you agree that Daiichi Sankyo, Inc. and our business partners may send you information about our products, programs and services from time to time. You will be able to cancel your participation at any time by using the unsubscribe link from emails. For further information about Daiichi Sankyo, Inc. privacy practices, please review our Terms and Conditions and Privacy Policy.

Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined.

Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined.

Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined.

Not an actual patient.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:

Cough
Trouble breathing or shortness of breath
Fever
Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

Low white blood cell count (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Heart problems that may affect your heart’s ability to pump blood. Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

New or worsening shortness of breath
Coughing
Feeling tired
Swelling of your ankles or legs

Irregular heartbeat
Sudden weight gain
Dizziness or feeling light-headed
Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

Have lung or breathing problems.
Have signs or symptoms of an infection.
Have or have had any heart problems.
Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
ENHERTU is given 1 time every three weeks (21-day treatment cycle).
Your healthcare provider will decide how many treatments you need.
Your healthcare provider will give medicines before your infusion to help prevent nausea and vomiting.
Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

Nausea
Low white blood cell counts
Low red blood cell counts
Feeling tired
Low platelet counts
Increased liver function tests
Vomiting

Hair loss
Constipation
Muscle or bone pain
Decreased appetite
Low levels of blood potassium
Diarrhea
Cough

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:

for metastatic disease, or
have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Back to Top